Adenovirus Vector Pseudotyping in Fiber-Expressing Cell Lines: Improved Transduction of Epstein-Barr Virus-Transformed B Cells
- 1 January 2000
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 74 (1) , 354-362
- https://doi.org/10.1128/jvi.74.1.354-362.2000
Abstract
While adenovirus (Ad) gene delivery vectors are useful in many gene therapy applications, their broad tropism means that they cannot be directed to a specific target cell. There are also a number of cell types involved in human disease which are not transducible with standard Ad vectors, such as Epstein-Barr virus (EBV)-transformed B lymphocytes. Adenovirus binds to host cells via the viral fiber protein, and Ad vectors have previously been retargeted by modifying the fiber gene on the viral chromosome. This requires that the modified fiber be able to bind to the cell in which the vector is grown, which prevents truly specific vector targeting. We previously reported a gene delivery system based on a fiber gene-deleted Ad type 5 (Ad5) vector (Ad5.βgal.ΔF) and packaging cells that express the viral fiber protein. Expression of different fibers in packaging cells will allow Ad retargeting without modifying the viral chromosome. Importantly, fiber proteins which can no longer bind to the producer cells can also be used. Using this approach, we generated for the first time pseudotyped Ad5.βgal.ΔF particles containing either the wild-type Ad5 fiber protein or a chimeric fiber with the receptor-binding knob domain of the Ad3 fiber. Particles equipped with the chimeric fiber bound to the Ad3 receptor rather than the coxsackievirus-adenovirus receptor protein used by Ad5. EBV-transformed B lymphocytes were infected efficiently by the Ad3-pseudotyped particles but poorly by virus containing the Ad5 fiber protein. The strategy described here represents a broadly applicable method for targeting gene delivery to specific cell types.Keywords
This publication has 106 references indexed in Scilit:
- Expression of the Primary Coxsackie and Adenovirus Receptor Is Downregulated during Skeletal Muscle Maturation and Limits the Efficacy of Adenovirus-Mediated Gene Delivery to Muscle CellsHuman Gene Therapy, 1999
- Gene Therapy Strategies for Treating Epstein–Barr Virus-Associated Lymphomas: Comparison of Two Different Epstein–Barr Virus-Based VectorsHuman Gene Therapy, 1998
- The ‘adenobody’ approach to viral targeting: specific and enhanced adenoviral gene deliveryGene Therapy, 1997
- Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5Science, 1997
- Killing Epstein-Barr Virus-Positive B Lymphocytes by Gene Therapy: Comparing the Efficacy of Cytosine Deaminase and Herpes Simplex Virus Thymidine KinaseHuman Gene Therapy, 1996
- Adenovirus mediated expression of therapeutic plasma levels of human factor IX in miceNature Genetics, 1993
- Gene therapy: adenovirus vectorsCurrent Opinion in Genetics & Development, 1993
- Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachmentCell, 1993
- Epstein-Barr virus in AIDS-related primary central nervous system lymphomaThe Lancet, 1991
- Detection of Epstein–Barr Viral Genomes in Reed–Sternberg Cells of Hodgkin's DiseaseNew England Journal of Medicine, 1989